Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 3, 2009, Pages 680-683

  Neale, Jason R ^a   Richter, Natali B ^b   Merten, Kevyn E ^c   Grant Taylor, K ^b   Singh, Sujan ^b   Waite, Leonard C ^a   Emery, Nicole K ^a   Smith, Ned B ^a   Cai, Jian ^a   Pierce Jr , William M ^a,b,c  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c Pradama Inc   (United States)

Author keywords

Bone targeted estrogen; Bone targeting; Hydroxyapatite; Osteoporosis; Osteotropic; Tetracycline

Indexed keywords

3 AMINO 2,6 DIHYDROXYBENZAMIDE; AMINE; BENZAMIDE DERIVATIVE; BONE TARGETED ESTROGEN A1; ESTRADIOL; ESTRADIOL DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HYDROXYAPATITE; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONJUGATE; CONJUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; RAT;

ANIMALS; BONE AND BONES; BONE DENSITY; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DURAPATITE; ESTRADIOL; ESTROGENS; FEMALE; OSTEOPOROSIS; OVARIECTOMY; PROTEIN SYNTHESIS INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; TETRACYCLINE;

RATTUS;

EID: 58549120543     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.12.051     Document Type: Article

References (20)

1. Fujisaki J., Tokunaga Y., Takahashi T., Hirose T., Shimojo F., Kagayama A., and Hata T. J. Drug Target. 3 (1995) 273
2. Sekido T., Sakura N., Higashi Y., Miya K., Nitta Y., Nomura M., Sawanishi H., Morito K., Masamune Y., Kasugai S., Yokogawa K., and Miyamoto K. J. Drug Target. 9 (2001) 111
3. Gil L., Han Y., Opas E.E., Rodan G.A., Ruel R., Seedor J.G., Tyler P.C., and Young R.N. Bioorg. Med. Chem. 7 (1999) 901
4. Uludag H. Curr. Pharm. Des. 8 (2002) 1929
5. Erez R., Ebner S., Attali B., and Shabat D. Bioorg. Med. Chem. Lett. 18 (2008) 816
6. Yokogawa K., Miya K., Sekido T., Higashi Y., Nomura M., Fujisawa R., Morito K., Masamune Y., Waki Y., Kasugai S., and Miyamoto K. Endocrinology 142 (2001) 1228
7. Fujisaki J., Tokunaga Y., Takahashi T., Shimojo F., Kimura S., and Hata T. J. Drug Target. 5 (1997) 129
8. Fujisaki J., Tokunaga Y., Takahashi T., Kimura S., Shimojo F., and Hata T. Biol. Pharm. Bull. 20 (1997) 1183
9. Stepensky D., Kleinberg L., and Hoffman A. Clin. Pharmacokinet. 42 (2003) 863
10. Hirabayashi H., and Fujisaki J. Clin. Pharmacokinet. 42 (2003) 1319
11. Skinner H.C., and Nalbandian J. Yale J. Biol. Med. 48 (1975) 377
12. Pierce W.M., and Waite L.C. Proc. Soc. Exp. Biol. Med. 186 (1987) 96
13. Orme M.W., and Labroo V.M. Bioorg. Med. Chem. Lett. 4 (1994) 1375
14. Wang D., Miller S.C., Kopecková P., and Kopecek J. Adv. Drug Delivery Rev. 57 (2005) 1049
15. Albert, A. In Selective Toxicity; John Wiley and Sons: New York, 1979, pp 431-433.
16. Korst J.J., Johnston J.D., Butler K., Bianco E.J., Conover L.H., and Woodward R.B. J. Am. Chem. Soc. 90 (1968) 439
17. Myers H.M., Tochon-Danguy H.J., and Baud C.A. Calcif. Tissue Int. 35 (1983) 745
18. max, and the molar concentration of the analyte was then determined using the Beer-Lambert Law and the previously calculated extinction coefficient. The fraction adsorbed to HA for each sample was calculated.
19. 3H]-estradiol present.
20. Kalu D.N. Bone Miner. 15 (1991) 175